Compare Carvana Co (CVNA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs GeneDx Holdings Corp — how do they compare? Carvana Co trades at $63.68 (market cap $69.55B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Carvana Co is far larger — about 34.4× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 7,671,750). Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and GeneDx Holdings Corp for 19 Days on average.
| CVNA | WGS | |
|---|---|---|
Market Cap | $69.55B | $2.02B |
Volume | 7,671,750 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $167.51 |
52-Week Low | $56.27 | $34.51 |
Typical Hold Time | 28 Days | 19 Days |
Enterprise Value | $72.04B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $64.26, up 2.39% on the day, showing resilience amid a bearish technical signal. The company reported strong revenue growth to $20.32B in 2025 with net income of $1.41B, and has beaten EPS estimates for three consecutive quarters. Positive analyst sentiment is highlighted by a consensus price target of $84.07, though technical indicators suggest near-term caution with key support at $61.
Outlook remains positive due to robust earnings beats and expansion initiatives, but risks include high debt levels and competitive pressures. The stock offers growth potential if operational execution continues, yet investors should monitor cash flow sustainability and market volatility.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
